I-Mab Logo
Contact Us For inquiries, get in touch with our team
  • Who We Are

    A global innovative biotech company

  • Value Creation

    Laser-focused on delivering innovative therapies to patients in need

  • Leadership Team

    A world-class global leadership team

  • People and Culture

    People are the cornerstone of our success

  • Commitment to ESG

    Committed to the highest environmental, social and governance standard

  • Science

    Our cutting-edge science focuses on fine-tuning the immune network in cancer

  • Operations

    An integrated research, development, manufacturing and commercialisation strategy

  • Publications & Presentations

    A compilation of our latest publications and presentations

  • Pipeline

    We have an innovative and advanced immuno-oncology clinical pipeline

  • Clinical Trials

    We work closely with global investigators to carefully conduct and monitor clinical studies

  • Partnerships

    We partner to deliver innovative medicines that transform patients' lives

  • News
  • Events
  • Mission and Values
  • Highlights
  • Awards
  • Value Creation Model
  • Value Creation Enabler
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Employee Development
  • Employee Wellness
  • Diversity, Inclusion and Equity
  • T+ Excellent Employer Award
  • Patients
  • Philanthropy
  • People
  • ESG Policies
  • Unmet Needs
  • Cutting-Edge Science
  • Key Products
  • Lemzoparlimab (TJC4)
  • Uliledlimab (TJD5)
  • Givastomig (TJ-CD4B)
  • Efineptakin alfa (TJ107)
  • TJ-C64B
  • Enoblituzumab (TJ271)
  • TJ-C4GM
  • TJ-L1I7
  • Hematologic Malignancies
  • Solid Tumors
  • Other Assets
  • Putting Patients First
  • Advancing Clinical Research
  • Selected Ongoing Clinical Trials
  • Strategic Partnering Model
  • Landmark Deals
  • Our Partners
  • Press Releases
  • Media Reports
  • Partner News
About Innovation Products Partnerships Newsroom
Investors Careers Contact Us
  • 中
I-Mab Logo
  • About
    • Who We Are
    • Value Creation
    • Leadership Team
    • People and Culture
    • Commitment to ESG
  • Innovation
    • Science
    • Operations
    • Publications & Presentations
  • Products
    • Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
  • Investors
  • Careers
  • Contact
  • Locations
  • 中

Press Releases

  • Press Releases
  • Media Reports
  • Partner News

2023.09.05

I-Mab Announces Upcoming Participation at September Conferences

I-Mab announced participation in investor conferences in September 2023.

2023.08.17

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

The Company today announced its financial results for the 6 months ended June 30, 2023, and provided key business updates.

2023.08.08

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab will host an investor call to report interim earnings on Aug 17.

2023.07.05

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

The Company published a manuscript in JITC demonstrating mechanism of givastomig in the treatment of CLDN18.2-expressing tumors through the targeted activation of 4-1BB mediated T cells.

2023.06.22

I-Mab Announces the Appointment of Raj Kannan as CEO

Mr. Raj Kannan joins the Company as Chief Executive Officer and a member of the board of directors.

2023.05.26

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.

2023.04.26

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

The Company will present a poster featuring the latest clinical data of uliledlimab in combination with PD-1 therapy in NSCLC at ASCO 2023.

2023.04.25

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute.

2023.04.24

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

The first patient in a Phase 3 registrational trial in China for patients with HR-MDS has been dosed with lemzoparlimab in combination with AZA.

2023.03.31

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

The Company today announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.

Posts navigation

1 2 3 4 … 19 Next

Sitemap

  • Home
  • About
  • Innovation
  • Products
  • Partnerships
  • News & Events
  • Investors
  • Careers
  • Contact
  • Locations
  • 中

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2023 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号